aTyr (ATYR) - שולי הרווח הגולמי

Under the leadership of Sanjay Shukla, the aTyr Pharma, Inc. (ATYR) team maintains strict operational discipline during the final stages of trials. Gross margin stability confirms this status, with 0.00 shaping the current metric. Revenue is based on the implementation of efzofitimod for the therapy of sarcoidosis, while risks are mitigated through the development of tRNA proteins to combat oncology and inflammation.
פילוחי מדדים פיננסיים ומדדי שוק עבור aTyr Pharma, Inc. (ATYR)

Gross margin determines the share of profit after deducting direct production costs, reflecting the efficiency of cost management and the product's pricing power. Analyzing changes in gross margin is critical for asset stress testing, as the outsourcing of clinical trials and manufacturing at aTyr Pharma (ATYR) allows the company to minimize capital expenditures, transforming fixed costs into variable costs to maintain flexibility.